A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion

Detalhes bibliográficos
Autor(a) principal: Vigant, Frederic
Data de Publicação: 2013
Outros Autores: Lee, Jihye, Hollmann, Axel, Tanner, Lukas B., Ataman, Zeynep Akyol, Yun, Tatyana, Shui, Guanghou, Aguilar, Hector C., Zhang, Dong, Meriwether, David, Roman-Sosa, Gleyder, Robinson, Lindsey R., Juelich, Terry L., Buczkowski, Hubert, Chou, Sunwen, Castanho, Miguel A. R. B., Wolf, Mike C., Smith, Jennifer K., Banyard, Ashley, Kielian, Margaret, Reddy, Srinivasa, Wenk, Markus R., Selke, Matthias, Santos, Nuno C., Freiberg, Alexander N., Jung, Michael E., Lee, Benhur
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/10708
Resumo: © 2013 Vigant et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
id RCAP_5f41e4b1092bfd127b8df7288b5f22b9
oai_identifier_str oai:repositorio.ul.pt:10451/10708
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion© 2013 Vigant et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.LJ001 is a lipophilic thiazolidine derivative that inhibits the entry of numerous enveloped viruses at non-cytotoxic concentrations (IC50≤0.5 mM), and was posited to exploit the physiological difference between static viral membranes and biogenic cellular membranes. We now report on the molecular mechanism that results in LJ001’s specific inhibition of viruscell fusion. The antiviral activity of LJ001 was light-dependent, required the presence of molecular oxygen, and was reversed by singlet oxygen (1O2) quenchers, qualifying LJ001 as a type II photosensitizer. Unsaturated phospholipids were the main target modified by LJ001-generated 1O2. Hydroxylated fatty acid species were detected in model and viral membranes treated with LJ001, but not its inactive molecular analog, LJ025. 1O2-mediated allylic hydroxylation of unsaturated phospholipids leads to a trans-isomerization of the double bond and concurrent formation of a hydroxyl group in the middle of the hydrophobic lipid bilayer. LJ001-induced 1O2-mediated lipid oxidation negatively impacts on the biophysical properties of viral membranes (membrane curvature and fluidity) critical for productive virus-cell membrane fusion. LJ001 did not mediate any apparent damage on biogenic cellular membranes, likely due to multiple endogenous cytoprotection mechanisms against phospholipid hydroperoxides. Based on our understanding of LJ001’s mechanism of action, we designed a new class of membrane-intercalating photosensitizers to overcome LJ001’s limitations for use as an in vivo antiviral agent. Structure activity relationship (SAR) studies led to a novel class of compounds (oxazolidine-2,4-dithiones) with (1) 100-fold improved in vitro potency (IC50<10 nM), (2) red-shifted absorption spectra (for better tissue penetration), (3) increased quantum yield (efficiency of 1O2 generation), and (4) 10–100-fold improved bioavailability. Candidate compounds in our new series moderately but significantly (p≤0.01) delayed the time to death in a murine lethal challenge model of Rift Valley Fever Virus (RVFV). The viral membrane may be a viable target for broad-spectrum antivirals that target virus-cell fusion.This work was supported by NIH grants U01 AI070495, U01 AI082100, R01 AI069317, U54 AI065359 (PSWRCE) (to BL), AI075647 (to MK), NIH-NIGMS 5SC1GM084776 (to DZ and MS), and by Fundação para a Ciência e a Tecnologia – Ministério da Educação e Ciêcia (Portugal) project PTDC/SAU-BEB/099142/2008 (to NCS) and fellowship SFRH/BPD/72037/2010 (to AH) and Veterans Affairs research funds (SC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.PLOSRepositório da Universidade de LisboaVigant, FredericLee, JihyeHollmann, AxelTanner, Lukas B.Ataman, Zeynep AkyolYun, TatyanaShui, GuanghouAguilar, Hector C.Zhang, DongMeriwether, DavidRoman-Sosa, GleyderRobinson, Lindsey R.Juelich, Terry L.Buczkowski, HubertChou, SunwenCastanho, Miguel A. R. B.Wolf, Mike C.Smith, Jennifer K.Banyard, AshleyKielian, MargaretReddy, SrinivasaWenk, Markus R.Selke, MatthiasSantos, Nuno C.Freiberg, Alexander N.Jung, Michael E.Lee, Benhur2014-03-10T12:35:32Z20132013-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/10708engPLOS Pathogens April 2013, Volume 9, Issue 4, e10032971553-7366http://dx.doi.org/10.1371/journal.ppat.1003297info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T15:56:23Zoai:repositorio.ul.pt:10451/10708Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:34:38.911548Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion
title A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion
spellingShingle A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion
Vigant, Frederic
title_short A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion
title_full A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion
title_fullStr A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion
title_full_unstemmed A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion
title_sort A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion
author Vigant, Frederic
author_facet Vigant, Frederic
Lee, Jihye
Hollmann, Axel
Tanner, Lukas B.
Ataman, Zeynep Akyol
Yun, Tatyana
Shui, Guanghou
Aguilar, Hector C.
Zhang, Dong
Meriwether, David
Roman-Sosa, Gleyder
Robinson, Lindsey R.
Juelich, Terry L.
Buczkowski, Hubert
Chou, Sunwen
Castanho, Miguel A. R. B.
Wolf, Mike C.
Smith, Jennifer K.
Banyard, Ashley
Kielian, Margaret
Reddy, Srinivasa
Wenk, Markus R.
Selke, Matthias
Santos, Nuno C.
Freiberg, Alexander N.
Jung, Michael E.
Lee, Benhur
author_role author
author2 Lee, Jihye
Hollmann, Axel
Tanner, Lukas B.
Ataman, Zeynep Akyol
Yun, Tatyana
Shui, Guanghou
Aguilar, Hector C.
Zhang, Dong
Meriwether, David
Roman-Sosa, Gleyder
Robinson, Lindsey R.
Juelich, Terry L.
Buczkowski, Hubert
Chou, Sunwen
Castanho, Miguel A. R. B.
Wolf, Mike C.
Smith, Jennifer K.
Banyard, Ashley
Kielian, Margaret
Reddy, Srinivasa
Wenk, Markus R.
Selke, Matthias
Santos, Nuno C.
Freiberg, Alexander N.
Jung, Michael E.
Lee, Benhur
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Vigant, Frederic
Lee, Jihye
Hollmann, Axel
Tanner, Lukas B.
Ataman, Zeynep Akyol
Yun, Tatyana
Shui, Guanghou
Aguilar, Hector C.
Zhang, Dong
Meriwether, David
Roman-Sosa, Gleyder
Robinson, Lindsey R.
Juelich, Terry L.
Buczkowski, Hubert
Chou, Sunwen
Castanho, Miguel A. R. B.
Wolf, Mike C.
Smith, Jennifer K.
Banyard, Ashley
Kielian, Margaret
Reddy, Srinivasa
Wenk, Markus R.
Selke, Matthias
Santos, Nuno C.
Freiberg, Alexander N.
Jung, Michael E.
Lee, Benhur
description © 2013 Vigant et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
publishDate 2013
dc.date.none.fl_str_mv 2013
2013-01-01T00:00:00Z
2014-03-10T12:35:32Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/10708
url http://hdl.handle.net/10451/10708
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv PLOS Pathogens April 2013, Volume 9, Issue 4, e1003297
1553-7366
http://dx.doi.org/10.1371/journal.ppat.1003297
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv PLOS
publisher.none.fl_str_mv PLOS
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134241582219264